Open AccessLipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels
Author(s) -
Kishor M. Wasan,
Frank W. Strobel,
Steven C. Parrott,
Melvyn Lynn,
William J. Christ,
Lynn D. Hawkins,
Daniel P. Rossignol
Publication year - 1999
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.43.10.2562
Subject(s) - lipoprotein , triglyceride , antagonist , endocrinology , medicine , high density lipoprotein , distribution (mathematics) , low density lipoprotein , chemistry , low density lipoprotein receptor related protein 8 , plasma protein binding , cholesterol , very low density lipoprotein , biology , biochemistry , receptor , mathematical analysis , mathematics
The purpose of this study was to determine the distribution profile of a novel endotoxin antagonist, [14 C]E5531, at 1 μg/ml in plasma samples obtained from fasted human subjects with various lipid and protein concentrations. Our findings suggest that the majority of E5531 binds with high-density lipoproteins (HDLs) independently of plasma lipid and protein levels tested. Furthermore, it appears that an increase in triglyceride-rich lipoprotein (TRL) lipid and protein levels and an increase in low-density lipoprotein (LDL) lipid levels significantly increase TRL plus LDL binding of E5531. However, only an increase in HDL protein levels significantly increases HDL binding of E5531.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom